Dekai Banerjee
ID
Ginpreet Kaur
ID
 Email src
Bappaditya Chatterjee
ID
Hemant Joshi
ID
Seema Ramniwas
ID
Hardeep Singh Tuli
ID
SVKM’s Narsee Monjee Institute of Management Studies, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, Mumbai, India
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM’s Narsee Monjee Institute of Management Studies, Vile Parle, Mumbai, India
SVKM’s Narsee Monjee Institute of Management Studies, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, Mumbai, India
School of Biotechnology, Jawaharlal Nehru University, New Delhi, India
University Centre for Research and Development, University Institute of Pharmaceutical Sciences, Chandigarh University, Gharuan, Mohali, India
Department of Bio-Sciences and Technology, MMEC, Maharishi Markandeshwar (Deemed to be University), Haryana, India
Received: 2 July 2023 / Revised: 15 July 2023 / Accepted: 17 July 2023 / Published: 30 September 2023

Abstract

Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation.

Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE.

Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies.

Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.

 

Cite

Banerjee D, Kaur G, Chatterjee B, Joshi H, Ramniwas S, Tuli HS. Effectiveness of novel iron regulators in the treatment of diabetic nephropathy. Eur J Clin Exp Med. 2023;21(3):639–647. doi: 10.15584/ejcem.2023.3.28.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited